In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Tuesday, Sept. 8, 2020, the top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus said that they will stick to the highest ethical and scientific standards in testing and manufacturing and will make the well-being of those getting vaccinated their top priority. (AP Photo/Hans Pennink)
By Linda A. Johnson
The top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus signed an unprecedented pledge meant to boost public confidence in any approved vaccines.
The companies said Tuesday that they will stick to the highest ethical and scientific standards in testing and manufacturing and will make the well-being of those getting vaccinated their top priority.
The announcement comes amid worries that the U.S. Food and Drug Administration will be under political pressure to approve a vaccine before tests to prove it is safe and effective are finished.
Meanwhile, public health officials worry that if many Americans don't get the vaccine, it will be harder to reduce the spread of COVID-19.
The pledge was signed by the chief executive officers of American drugmakers Johnson & Johnson, Merck, Moderna, Novavax, and Pfizer, and European companies AstraZeneca, BioNTech, GlaxoSmithKline, and Sanofi. BioNTech has partnered with Pfizer on one of the vaccines now in the final round of human testing.
Allison Pohle, reporter at The Wall Street Journal, breaks down airline chaos, surprise winners, and what the latest rankings mean for your next flight.
Jason Chinnock discusses Ducati’s 100th anniversary, blending a century of racing heritage with innovation, off-road expansion, and plans for the next 100 years
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
For Trump, markets matter more than polls. Luke Broadwater, White House correspondent for The New York Times, examines how Wall Street guides decisions.
As political and economic uncertainty rises, Americans are seeking second passports and golden visas. Latitude Group’s CEO explains what’s driving the surge.
As AI and electrification drive record power demand, nuclear energy returns to the spotlight. Lightbridge CEO explains how advanced fuel could reshape the grid.
Shark Tank’s Kevin O’Leary breaks down his Hollywood debut, Marty Supreme’s $100M box office run, Oscar buzz, and what business taught him about movies.
